Tarsus (TARS) CEO Bobak Azamian Sells 10,000 Shares

What Happened Bobak Azamian, President, CEO and Chair of Tarsus Pharmaceuticals (TARS), sold a total of 10,000 shares in two open-market transactions on September 4, 2026, for aggregate proceeds of about $905,600. The filing reports 7,100 shares sold at a weighted average price of $90.27 (proceeds $640,917) and 2,900 shares sold at a weighted average price of $91.27 (proceeds $264,683). These sales were effected under a Rule 10b5-1 trading plan adopted December 9, 2025.

Key Details

• Transaction dates: September 4, 2026 (both tranches).
• Prices reported (weighted averages): $90.27 for 7,100 shares; $91.27 for 2,900 shares.
• Price ranges per filing: first tranche traded between $90.00–$90.91; second tranche between $91.06–$91.45. The reporting person will provide full per-price breakdown upon request (per footnotes).
• Total shares sold: 10,000; total proceeds: ~$905,600.
• Reporting role: Azamian is trustee of the Bobak Azamian Living Trust and has voting/dispositive power over these shares.
• Plan type: Sales were automatic under a Rule 10b5-1 plan (adopted Dec 9, 2025).
• Shares owned after transaction: not disclosed in the Form 4 filing.
• Filing timeliness: Form filed Sept 9, 2026 for a Sept 4 transaction (filed five days after the transaction); Form 4s are normally required within two business days, so this appears later than the usual window.

Context

• These were planned sales under a pre-established 10b5-1 plan, which is commonly used to sell holdings on a set schedule and is generally considered routine rather than a direct signal of the insider’s view.
• For retail investors, purchases by insiders can be more informative than routine sales; this filing documents a divestiture under an automated plan rather than an opportunistic open-market trade timed by the insider.